Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative

Zhihua Li, Bradley J. Ridder, Xiaomei Han, Wendy Wu, Jiansong Sheng, Phu N. Tran, Min Wu, Aaron Randolph, Ross H. Johnstone, Gary R. Mirams, Yuri Kuryshev, James Kramer, Caiyun Wu, William J. Crumb, David G. Strauss

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The International Council on Harmonization (ICH) S7B and E14 regulatory guidelines are sensitive but not specific for predicting which drugs are pro-arrhythmic. In response, the Comprehensive In Vitro Proarrhythmia Assay (CiPA) was proposed that integrates multi-ion channel pharmacology data in vitro into a human cardiomyocyte model in silico for proarrhythmia risk assessment. Previously, we reported the model optimization and proarrhythmia metric selection based on CiPA training drugs. In this study, we report the application of the prespecified model and metric to independent CiPA validation drugs. Over two validation datasets, the CiPA model performance meets all pre-specified measures for ranking and classifying validation drugs, and outperforms alternatives, despite some in vitro data differences between the two datasets due to different experimental conditions and quality control procedures. This suggests that the current CiPA model/metric may be fit for regulatory use, and standardization of experimental protocols and quality control criteria could increase the model prediction accuracy even further.

Original languageEnglish (US)
JournalClinical Pharmacology and Therapeutics
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Fingerprint

Computer Simulation
Quality Control
Pharmaceutical Preparations
In Vitro Techniques
Ion Channels
Cardiac Myocytes
Pharmacology
Guidelines

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative. / Li, Zhihua; Ridder, Bradley J.; Han, Xiaomei; Wu, Wendy; Sheng, Jiansong; Tran, Phu N.; Wu, Min; Randolph, Aaron; Johnstone, Ross H.; Mirams, Gary R.; Kuryshev, Yuri; Kramer, James; Wu, Caiyun; Crumb, William J.; Strauss, David G.

In: Clinical Pharmacology and Therapeutics, 01.01.2018.

Research output: Contribution to journalArticle

Li, Z, Ridder, BJ, Han, X, Wu, W, Sheng, J, Tran, PN, Wu, M, Randolph, A, Johnstone, RH, Mirams, GR, Kuryshev, Y, Kramer, J, Wu, C, Crumb, WJ & Strauss, DG 2018, 'Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative', Clinical Pharmacology and Therapeutics. https://doi.org/10.1002/cpt.1184
Li, Zhihua ; Ridder, Bradley J. ; Han, Xiaomei ; Wu, Wendy ; Sheng, Jiansong ; Tran, Phu N. ; Wu, Min ; Randolph, Aaron ; Johnstone, Ross H. ; Mirams, Gary R. ; Kuryshev, Yuri ; Kramer, James ; Wu, Caiyun ; Crumb, William J. ; Strauss, David G. / Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative. In: Clinical Pharmacology and Therapeutics. 2018.
@article{03b87b3a8efb4e83821c5dae13317cbf,
title = "Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative",
abstract = "The International Council on Harmonization (ICH) S7B and E14 regulatory guidelines are sensitive but not specific for predicting which drugs are pro-arrhythmic. In response, the Comprehensive In Vitro Proarrhythmia Assay (CiPA) was proposed that integrates multi-ion channel pharmacology data in vitro into a human cardiomyocyte model in silico for proarrhythmia risk assessment. Previously, we reported the model optimization and proarrhythmia metric selection based on CiPA training drugs. In this study, we report the application of the prespecified model and metric to independent CiPA validation drugs. Over two validation datasets, the CiPA model performance meets all pre-specified measures for ranking and classifying validation drugs, and outperforms alternatives, despite some in vitro data differences between the two datasets due to different experimental conditions and quality control procedures. This suggests that the current CiPA model/metric may be fit for regulatory use, and standardization of experimental protocols and quality control criteria could increase the model prediction accuracy even further.",
author = "Zhihua Li and Ridder, {Bradley J.} and Xiaomei Han and Wendy Wu and Jiansong Sheng and Tran, {Phu N.} and Min Wu and Aaron Randolph and Johnstone, {Ross H.} and Mirams, {Gary R.} and Yuri Kuryshev and James Kramer and Caiyun Wu and Crumb, {William J.} and Strauss, {David G.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/cpt.1184",
language = "English (US)",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative

AU - Li, Zhihua

AU - Ridder, Bradley J.

AU - Han, Xiaomei

AU - Wu, Wendy

AU - Sheng, Jiansong

AU - Tran, Phu N.

AU - Wu, Min

AU - Randolph, Aaron

AU - Johnstone, Ross H.

AU - Mirams, Gary R.

AU - Kuryshev, Yuri

AU - Kramer, James

AU - Wu, Caiyun

AU - Crumb, William J.

AU - Strauss, David G.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The International Council on Harmonization (ICH) S7B and E14 regulatory guidelines are sensitive but not specific for predicting which drugs are pro-arrhythmic. In response, the Comprehensive In Vitro Proarrhythmia Assay (CiPA) was proposed that integrates multi-ion channel pharmacology data in vitro into a human cardiomyocyte model in silico for proarrhythmia risk assessment. Previously, we reported the model optimization and proarrhythmia metric selection based on CiPA training drugs. In this study, we report the application of the prespecified model and metric to independent CiPA validation drugs. Over two validation datasets, the CiPA model performance meets all pre-specified measures for ranking and classifying validation drugs, and outperforms alternatives, despite some in vitro data differences between the two datasets due to different experimental conditions and quality control procedures. This suggests that the current CiPA model/metric may be fit for regulatory use, and standardization of experimental protocols and quality control criteria could increase the model prediction accuracy even further.

AB - The International Council on Harmonization (ICH) S7B and E14 regulatory guidelines are sensitive but not specific for predicting which drugs are pro-arrhythmic. In response, the Comprehensive In Vitro Proarrhythmia Assay (CiPA) was proposed that integrates multi-ion channel pharmacology data in vitro into a human cardiomyocyte model in silico for proarrhythmia risk assessment. Previously, we reported the model optimization and proarrhythmia metric selection based on CiPA training drugs. In this study, we report the application of the prespecified model and metric to independent CiPA validation drugs. Over two validation datasets, the CiPA model performance meets all pre-specified measures for ranking and classifying validation drugs, and outperforms alternatives, despite some in vitro data differences between the two datasets due to different experimental conditions and quality control procedures. This suggests that the current CiPA model/metric may be fit for regulatory use, and standardization of experimental protocols and quality control criteria could increase the model prediction accuracy even further.

UR - http://www.scopus.com/inward/record.url?scp=85052820080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052820080&partnerID=8YFLogxK

U2 - 10.1002/cpt.1184

DO - 10.1002/cpt.1184

M3 - Article

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

ER -